Mereo BioPharma (MREO) Cash from Investing Activities (2023 - 2026)
Mereo BioPharma (MREO) reported Cash from Investing Activities of -$300000.0 for Q1 2026, up 6.25% year-over-year from -$282352.9 in Q1 2025, and down 200.0% quarter-over-quarter from $300000.0 in Q3 2025.
Mereo BioPharma (MREO) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Mereo BioPharma (MREO) has 4 years of Cash from Investing Activities data on file, last reported at -$300000.0 in Q1 2026.
- Cash from Investing Activities for Q1 2026 came in at -$300000.0, up 6.25% year-over-year; the trailing twelve-month figure through Dec 2025 was -$20000.0 (up 97.14% YoY), and the FY2025 annual result was -$20000.0, up 97.14% from the prior year.
- Cash from Investing Activities eased to -$300000.0 in Q1 2026 per MREO's latest filing, from $300000.0 in the prior quarter.
- Over five years, Cash from Investing Activities peaked at $300000.0 in Q3 2025 and troughed at -$700000.0 in Q1 2024.
- A 4-year average of -$239666.7 and a median of -$310000.0 in 2025 frame the typical range for Cash from Investing Activities.
- The sharpest annual moves came in 2024 and 2025: Cash from Investing Activities plunged 67.06% in 2024, then surged 54.29% in 2025.
- A 4-year view of Cash from Investing Activities shows it stood at -$419000.0 in 2023, then surged by 100.24% to $1000.0 in 2024, then surged by 29900.0% to $300000.0 in 2025, then sank by 200.0% to -$300000.0 in 2026.
- Business Quant data shows MREO's Cash from Investing Activities at -$300000.0 in Q1 2026, $300000.0 in Q3 2025, and -$320000.0 in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 579,519.10 |
| 10 | Mereo BioPharma | 252.49 Mn | 252.49 Mn | - | -300,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -300,000.00 |
| Mar 31, 2026 | -300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Sep 30, 2025 | 300,000.00 |
| Mar 31, 2025 | -320,000.00 |
| Mar 31, 2025 | -320,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Jun 30, 2024 | 1,000.00 |
| Mar 31, 2024 | -700,000.00 |
| Mar 31, 2024 | -700,000.00 |
| Mar 31, 2023 | -419,000.00 |
| Mar 31, 2023 | -419,000.00 |